|
1.
|
Surveillance, Epidemiology and End Results
(SEER) Web site: Available online: http://www.seer.cancer.govApril2010
based on the November 2009 submission.
|
|
2.
|
Beck-Peccoz P and Persani L: Premature
ovarian failure. Orphanet J Rare Dis. 1:92006. View Article : Google Scholar
|
|
3.
|
Sonmezer M and Oktay K: Fertility
preservation in female patients. Hum Reprod Update. 10:251–266.
2004. View Article : Google Scholar
|
|
4.
|
Bokser L, Szende B and Schally AV:
Protective effects of D-Trp6-luteinizing hormone-releasing hormone
microcapsules against cyclophosphamide-induced gonadotoxicity in
female rats. Br J Cancer. 61:861–865. 1990. View Article : Google Scholar
|
|
5.
|
Ataya K, Rao LV, Lawrence E and Kimmel R:
Luteinizing hormone-releasing hormone agonist inhibits
cyclophosphamide-induced ovarian follicular depeletion in rhesus
monkeys. Biol Reprod. 52:365–372. 1995. View Article : Google Scholar
|
|
6.
|
Del Mastro L, Catzeddu T, Boni L, et al:
Prevention of chemotherapy-induced menopause by temporary ovarian
suppression with goserelin in young, early breast cancer patients.
Ann Oncol. 17:74–78. 2006.PubMed/NCBI
|
|
7.
|
Clowse ME, Behera MA, Anders CK, Copland
S, et al: Ovarian preservation by GnRH agonists during
chemotherapy: A meta-analysis. J Women’s Health. 18:311–319.
2009.PubMed/NCBI
|
|
8.
|
Yang B, Shi W, Yang J, Liu H, Zhao H, et
al: Concurrent treatment with gonadotropin-releasing hormone
agonists for chemotherapy-induced ovarian damage in premenopausal
women with breast cancer: A meta-analysis of randomized controlled
trials. Breast. 22:150–157. 2013. View Article : Google Scholar
|
|
9.
|
Turner NH, Partridge A, Sanna G, Di Leo A
and Biganzoli L: Utility of gonadotropin-releasing hormone agonists
forfertility preservation in young breast cancer patients: the
benefit remains uncertain. Ann Oncol. 24:2224–2235. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Higgins JPT and Green S: Cochrane Handbook
for Systematic Reviews of Interventions. Version 5.1.0. The Cohran
Collaboration (updated March 2011).
|
|
11.
|
Badawy A, Elnashar A, El-Ashry M and
Shahat M: Gonadotropin-releasing hormone agonists for prevention of
chemotherapy-induced ovarian damage: prospective randomized study.
Fertil Steril. 91:694–697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Munster PN, Moore AP, et al: Randomized
trial using gonadotropin-releasing hormone agonist triptorelin for
the preservation of ovarian function during (neo)adjuvant
chemotherapy for breast cancer. J Clin Oncol. 30:533–538. 2012.
View Article : Google Scholar
|
|
13.
|
Waxman JH, Ahmed R, Smith D, Wrigley PEM,
et al: Failure to preserve fertility in patients with Hodgkin’s
disease. Cancer Chemother Pharmacol. 19:159–162. 1987.
|
|
14.
|
Loverro G, Guarini A, Di Naro E, et al:
Ovarian function after cancer treatment in young women affected by
Hodgkin disease (HD). Hematology. 12:141–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Del Mastro L, Boni L, Michelotti A,
Gamucci T, Olmeo N, et al: Effect of the gonadotropin-releasing
hormone analogue triptorelin on the occurrence of
chemotherapy-induced early menopause in premenopausal women with
breast cancer: a randomized trial. JAMA. 306:269–276. 2011.
|
|
16.
|
Elgindy EA, El-Haieg DO, Khorshid OM, et
al: Gonadatrophin suppression to prevent chemotherapy-induced
ovarian damage: a randomized controlled trial. Obstet Gynecol.
121:78–86. 2013.PubMed/NCBI
|
|
17.
|
Gerber B, von Minlkwitz G, Stehle H,
Reimer T, et al: Effect of luteining hormone-releasing hormone
agonist on ovarian function after modern adjuvant breast cancer
therapy: The GBG 37 ZORO study. J Clin Oncol. 29:2334–2341. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gilani MM, Hasanzadeh M, Ghaemmaghami F,
et al: Ovarian preservation with gonadotrop in releasing hormone
analog during chemotherapy. Asia Pac J Clin Oncol. 3:79–83. 2007.
View Article : Google Scholar
|
|
19.
|
Blumenfeld Z: How to preserve fertility in
young women exposed to chemotherapy? The role of GnRH agonist
cotreatment in addition to cryopreservation of embryo, oocytes, or
ovaries. Oncologist. 12:1044–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Goswami D and Conway GS: Premature ovarian
failure. Hum Reprod Update. 11:391–410. 2005. View Article : Google Scholar
|
|
21.
|
Ravdin PM, Fritz NF, Tormey DC and Jordan
VC: Endocrine status of premenopausal node-positive breast cancer
patients following adjuvant chemotherapy and long-term tamoxifen.
Cancer Res. 48:1026–1029. 1989.PubMed/NCBI
|
|
22.
|
Anderson RA, Themmen AP, Al-Qahtani A,
Groome NP and Cameron DA: The effects of chemotherapy and long-term
gonadotropin suppression on the ovarian reserve in premenopausal
women with breast cancer. Hum Reprod. 21:2583–2592. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sverrisdottir A, Nystedt M, Johansson H
and Fornander T: Adjuvant goserelin and ovarian preservation in
chemotherapytreated patients with early breast cancer: results from
a randomized trial. Breast Cancer Res Treat. 117:561–567. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Partridge A, Gelber S, Gerber RD and
Castiglione-Certsch M: Age of menopause among women who remain
premenopausal following treatment for early breast cancer:
long-term results from International Breast Cancer Study Group
Trials V and VI. Eur J Cancer. 43:1646–1653. 2007. View Article : Google Scholar
|
|
25.
|
Te Velde ER and Pearson PL: The
variability of female reproductive ageing. Hum Reprod Upadate.
8:141–154. 2002.PubMed/NCBI
|
